Cancer cells survive cellular crisis through telomere maintenance mechanisms. We report telomere lengths in 18,430 samples, including tumors and non-neoplastic samples, across 31 cancer types. Telomeres were shorter in tumors than in normal tissues and longer in sarcomas and gliomas than in other cancers. Among 6,835 cancers, 73% expressed telomerase reverse transcriptase (TERT), which was associated with TERT point mutations, rearrangements, DNA amplifications and transcript fusions and predictive of telomerase activity. TERT promoter methylation provided an additional deregulatory TERT expression mechanism. Five percent of cases, characterized by undetectable TERT expression and alterations in ATRX or DAXX, demonstrated elongated telomeres and increased telomeric repeat-containing RNA (TERRA). The remaining 22% of tumors neither expressed TERT nor harbored alterations in ATRX or DAXX. In this group, telomere length positively correlated with TP53 and RB1 mutations. Our analysis integrates TERT abnormalities, telomerase activity and genomic alterations with telomere length in cancer.
Telomeres make up the terminal ends of each chromosome and are composed of repetitive DNA sequence (TTAGGG) n and bound proteins 1 . These complexes function by protecting the chromosome ends from being recognized as DNA double-strand breaks and preventing inadvertent activation of detrimental DNA damage response pathways 2 . Telomeres shorten with each cell division, which eventually triggers cellular senescence, resulting in growth arrest 3 . This process can be circumvented by inactivation of p53 and Rb tumor-suppressor proteins [4] [5] [6] [7] . Further cell division leads to cellular crisis and ultimately cell death. Cells can occasionally overcome crisis through the activation of a telomere maintenance mechanism.
Senescence and crisis are potent tumor-suppressive mechanisms 8 , and maintenance of telomere length is therefore an important step in oncogenesis. Telomere shortening can be counteracted by activation of telomerase 9 . The telomerase enzymatic subunit, encoded by TERT, is transcriptionally silent in most non-neoplastic cells, but reactivation may endow a small population of cells with the ability to survive crisis, at which point they become immortalized 10 . It has been proposed that up to 90% of human cancers reactivate telomerase 11 . Several mechanisms have since been associated with TERT reactivation, including TERT promoter mutations or rearrangements and DNA copy number amplifications [12] [13] [14] [15] . Alternative lengthening of telomeres (ALT), a homologous recombination-based process, is frequently observed in tumors lacking telomerase activity and manifests with long but highly variable telomeres 16, 17 . Deactivating mutations in ATRX and its binding partner DAXX were found to be tightly correlated with long telomeres in pancreatic neuroendocrine tumors 18 and gliomas 19 . Recent evidence suggested that loss of ATRX may contribute to ALT by promoting sustained sister telomere cohesion and chromatid exchange 20 .
Here, we analyzed 18,430 unique samples, including tumors (n = 9,065), blood controls (n = 7,643) and solid tissue controls (n = 1,722), from 9,127 patients and 31 cancer types, to identify genomic and transcriptomic characteristics of telomere length.
RESULTS

Telomere length in human cancer and matching normal tissue
Telomere length (TL) is expected to vary among tumor types owing to varying frequencies of ALT, different age distributions and variability of telomere lengths among cells of origin from different lineages. To quantify this heterogeneity, we estimated TL for 18,430 samples across 31 cancer cohorts available through The Cancer Genome Atlas (TCGA), including samples profiled using whole-genome sequencing (WGS, n = 2,018), low-pass whole-genome sequencing (LPS, n = 1,929); and whole-exome sequencing (WXS, n = 14,483) 21 ( Fig. 1a and Supplementary Table 1) . The full data set consisted of tumor samples, normal blood samples and solid tissue controls (Supplementary Fig. 1a ). Matching tumor and normal (T/N) samples were available from 8,953 unique patients ( Supplementary Fig. 1b) , and using T/N TL ratios alleviated technical effects from differences in sequencing center and method (Supplementary Fig. 2 ).
To compare TL across tumors and normal tissues, we used linear mixed modeling to adjust high-confidence WGS-based TL (n = 2,018) for confounding effects (Supplementary Table 2 ). In addition to 734 normal blood samples, this analysis included 213 normal tissue samples of five different tissue types, including liver (n = 21), lung (n = 46) and kidney (n = 81). We did not detect statistically significant differences between tissue types and confirmed considerable variability among samples from the same tissue type 22 ( Supplementary Fig. 3a,b) and negative correlation between TL and age ( Supplementary Fig. 3c ).
Across neoplastic samples, cervical (2.36 kb, 95% confidence interval (CI) 1.82-3.07 kb) and endometrial cancer (2.82 kb, 95% CI 2.32-3.42 kb) showed the shortest average TL, whereas glioma (5.69 kb, 95% CI 4.75-6.81 kb) and sarcoma (5.71 kb, 95% CI 4.63-7.05 kb) showed the longest (Fig. 1b) . Tumors showed TL shortening (tumor TL < normal TL) compared to matched normal samples in 70% of our cohort, and relative TL elongation (tumor TL > normal TL) in 30% ( Supplementary Fig. 1b ). Tumor types that showed the highest rates of relatively longer TLs included testicular germ cell tumors (52%), lower-grade glioma (54%) and sarcoma (55%), possibly reflecting the high telomerase activity seen in malignant testicular germ cell tumors 23 and the high frequency of ALT in lower-grade glioma and sarcoma. Conversely, uveal melanoma (100%), kidney chromophobe (89%), kidney papillary (n = 238/283, 84%) and lymphoma (84%) demonstrated the highest rates of relatively shorter TLs.
Multiple modalities associated with TERT overexpression
To catalog somatic alterations that may lead to overexpression of TERT in cancer, we performed a genomic and epigenetic TERT survey. We curated a core sample set of the 473 T/N pairs with the most comprehensive molecular profiling and an extended set of 6,835 T/N pairs with varying numbers of cases profiled by each platform (Fig. 1a and Online Methods). TERT promoter (TERTp) mutations, predominantly chr. 5: 1,295,228 C>T and chr. 5: 1,295,250 C>T, were detected in 27% of the cases in the extended set in which TERTp status could be determined (n = 1,581). In agreement with previous reports 24, 25 , high incidence of TERTp mutations was found in bladder cancer (42/60, 70%), liver cancer (73/162, 45%), melanoma (93/129, 72%), lower-grade glioma (127/285, 45%) and glioblastoma (25/28, 89%) ( Supplementary  Fig. 4a ). We found TERT focal amplifications in 4% of all samples, and these events were most frequently observed in ovarian cancer (6/27, 22%), lung adenocarcinoma (63/476, 13%), lung squamous cell carcinoma (23/167, 14%), esophageal carcinoma (23/168, 14%) and adrenocortical carcinoma (11/75, 15%) 14 (Supplementary Fig. 4b ). Structural variants involving TERT or TERTp were detected in 15 samples (3%) and 17 samples (4%) of the core set, respectively ( Fig. 2a  and Supplementary Table 3) . TERT or TERTp structural variants were most frequent in sarcoma (10/39, 26%), hepatocellular carcinoma (7/50, 14%), kidney chromophobe (5/49, 10%) and prostate cancer (2/20, 10%) (Supplementary Fig. 4c ).
TERTp rearrangements have been proposed to lead to juxtaposition of enhancer elements in neuroblastoma 15 . To investigate this hypothesis, we overlaid the genomic positions with a database of 65,950 super-enhancers across 107 tumor and normal cell types 26 . In the majority of TERTp structural variants (65%), at least one predicted super-enhancer was found to directly overlap with the juxtaposed position (Supplementary Table 3) . We compared signals of enhancer marks acetylation of histone H3 at K27 (H3K27ac) and monomethylation of H3 at K4 (H3K4me1) 27 for each of the breakpoints in the TERTp and the juxtaposed, distal breakpoints across 111 epigenomes available from the NIH Roadmap Epigenomics Consortium 28 and found significant enrichment for enhancer marks in the juxtaposed position compared to TERTp (Fig. 2b and Supplementary Fig. 4d ). Our data suggest that TERTp rearrangements may result in repositioning of enhancer elements that activate TERT transcription.
We next performed a supervised search for TERT gene fusions 29, 30 . TERT fusion transcripts were detected in 3% of the extended set ( Supplementary Fig. 5a and Supplementary n = 104 n = 141 n = 38 n = 100 n = 99 n = 46 n = 100 n = 114 n = 203 n = 88 n = 79 n = 71 n = 108 n = 74 n = 107 n = 40 n = 14 n = 100 n = 98 n = 96 n = 79 n = 79 a n a ly s i s fell in the second intron. Both exons 2 and 3 map to the telomerase RNA binding domain, and it is thus unlikely that the fusion product retains canonical TERT functionality 31, 32 . We observed read coverage on exon 2 in 15 of 16 samples, suggesting that additional TERT transcripts were expressed. Taken together, we found somatic TERT alterations, including TERTp mutations, TERT amplifications and TERT structural variants involving gene promoter or gene body, in 32% of core set samples. Somatic TERT alterations were associated with detectable TERT transcripts in 93%. Next, we evaluated whether epigenetic mechanisms could also be related to TERT transcriptional activation. We correlated TERT expression to DNA methylation probes mapping to the TERT gene body (n = 72) and promoter (n = 3). We observed moderate correlations between TERTp DNA methylation and TERT expression in samples carrying a somatic TERT alteration (false discovery rate (FDR) > 0.05, |ρ| < 0.3; Fig. 2a) . In contrast, samples lacking somatic TERT alterations showed significant negative correlation between gene body methylation and expression and positive correlation between promoter methylation and expression (Fig. 2a) . As previously described in pediatric brain tumors 33 , TERTp probe cg11625005 demonstrated a strong correlation with TERT expression (ρ = 0.52, FDR < 0.0001). Further comparison of this probe using 537 paired tumor and adjacent tissue normal samples showed a general absence of methylation of this probe in normal samples (Supplementary Fig. 5b ).
We found that 63% of tumors carrying wild-type TERT in the core set expressed TERT, of which 91% showed TERTp DNA methylation, whereas 40% of the TERT-nonexpressing samples showed TERTp methylation. Collectively, 95% of TERT-expressing samples showed TERTp mutations (31%), TERT amplification (3%), TERT structural variants (3%), TERTp structural variants (5%) or TERTp methylation (53%). Among different types of TERT aberrations, the TERTp structural variant group showed the highest transcription levels (twosided t-test P < 0.05; Fig. 2c ). TERTp methylation (two-sided t-test P < 0.05) and TERTp mutations (two-sided t-test P < 0.0001) were associated with relative TL shortening, as compared to other types of TERT alterations (Supplementary Fig. 5c ).
We next performed a similar analysis of TERC, the RNA subunit of the telomerase complex 34 . TERC was amplified in 4% of samples in the extended set, most frequently in lung squamous cell carcinoma (n = 68/167, 41%), esophageal cancer (n = 36/168, 21%) and ovarian cancer (n = 6/27, 22%). We did not identify mutations or structural variants targeting TERC. Focal TERC amplifications were associated with increased TERC expression (two-sided t-test P < 0.0001) (Supplementary Fig. 5d ) and were enriched in TERT-expressing samples (odds ratio (OR) 2.59, Fisher's exact P < 0.0001).
Inferring telomerase activity using a gene expression signature Previous studies have shown a complex role for transcription of TERT and its various isoforms in determining telomerase activity [35] [36] [37] , in TERT expression in TERT alt and WT groups. ***P < 0.0001; **P < 0.001; *P < 0.05, two-sided t-test. Meth, methylation; mut, mutation; amp, amplification; sv, structural variation. Boxes, interquartile range (IQR); center lines, median; whiskers, maximum and minimum or 1.5× IQR. a n a ly s i s part because only the full-length TERT transcript can encode enzymatically active protein 32 . The β-deletion (β − ) isoform skips exons 7 and 8 and prematurely stops at exon 10; it is thought to be the most abundant TERT splice variant in cancer 38, 39 (Supplementary Table 4) . We evaluated the presence of the β − transcripts in 1,201 samples with sufficient exon 6 to 9 coverage using MISO 40 ( Supplementary Fig. 6a ).
T E R T T E R T p m e th T E R T p m u t T E R T a m p T E R T p s v T E R T
Full-length transcripts were detected in all samples and were significantly more abundant than β − transcripts (one-sample t-test P < 0.0001, µ = 50%) ( Supplementary Fig. 6b ).
Given the limitations of TERT expression, as measured by RNAseq, in predicting telomerase activity and the lack of telomerase measurements in the TCGA proteomics data sets (data not shown), we inferred telomerase activity through a gene signature (Supplementary Table 4 ). The signature showed a positive correlation with telomerase enzymatic activities determined in urothelial cancer cell lines (n = 11, Supplementary Fig. 7a ) without reaching statistical significance 35 (P = 0.07). Telomerase activity scores were significantly higher in tumor samples than in various solid tissues (two-sided t-test P < 0.01) ( Supplementary Fig. 7b ), with kidney chromophobe carcinoma representing an exception. Both results suggested that the gene signature provided a general estimate of telomerase activity.
We found that telomerase signature scores were significantly higher in TERT-expressing cancers than nonexpressing cancers in both the core and extended sets (both P < 0.0001, Wilcoxon rank-sum test). Samples with TERT amplification scored highest, followed by promoter methylation, gene body and promoter structural variation and promoter mutation (Supplementary Fig. 7c ). TERC amplification was additionally associated with high telomerase signature scores compared to nonamplified samples (two-sided t-test, P < 0.0001), which may in part be explained by the coexpression patterns of TERT and TERC. Pan-cancer analysis using all 31 cancer types identified a positive correlation between TERT expression and telomerase signature score (ρ = 0.69, P < 0.0001), with testicular germ cell tumors showing the highest average scores and pheochromocytoma and paraganglioma the lowest (Supplementary Fig. 7d ).
Telomere elongation in ATRX-altered tumors
To identify TERT-independent mechanisms involved in TL regulation, we associated somatic alterations to TL ratio in the extended set. We reduced the search space by selecting genes significantly mutated, genes focally deleted or gained and genes included in a manually compiled list of telomere-associated genes (n = 196; Supplementary Table 5 ). Alterations of ATRX and IDH1 were the most significantly associated with relative TL elongation (both FDR < 0.0001; Fig. 3a) . Because IDH1 and ATRX mutations frequently co-occur in glioma, we tested a model with both tumor type and IDH1 as covariates, and found IDH1 no longer associated with TL ratio (two-sided t-test P = 0.15). Other hits (FDR < 0.25) associated with relative TL elongation included TP53 (TL ratio 1.15, 95% CI 1.1-1.21, FDR < 0.0001), BCOR (TL ratio 1.24, 95% CI 1.08-1.42, FDR = 0.04), RB1 (TL ratio 1.14, 95% CI 1.04-1.25, FDR = 0.05), CCNE1 (TL ratio 1.19, 95% CI 1.05-1.35, FDR = 0.07) and TERC (TL ratio 1.14, 95% CI 1.02-1.27, FDR = 0.16). Alterations of VHL were found to be associated with relative TL shortening (TL ratio 0.7, 95% CI 0.61-0.8, FDR < 0.0001). We repeated the analysis in each cancer type and found TP53 associated with relative TL elongation in six tumor types ( Supplementary  Fig. 8a ). Given the role of p53 in apoptosis regulation and senescence bypass, direct involvement of TP53 in telomere maintenance should be carefully tested in well-controlled conditions. A linear regression model showed that in addition to older age, positive TERRA expression, TP53 deletion, TP53 mutations, ATRX deletion, ATRX Figure 3 Multivariable genomic determinants of TL. (a) Gene to TL ratio associations using the extended set (n = 6,835). P values were calculated using a two-sided t-test and adjusted for multiple testing using FDR. (b) Heat map of TERT, TERC, ATRX and TP53 expression and somatic alterations in the core set (n = 473). TL ratio, TERRA expression and telomerase signature (sig) score are also shown. Each column represents a sample. (c) Linear regression analysis of TL ratio. Variables shown are independent predictors of TL in the core set (n = 473). Variables from b were selected using backwards elimination to derive the final model. R 2 = 0.16. Meth, methylation; mut, mutation; amp, amplification; sv, structural variation; fus, fusion; del, deletion. a n a ly s i s structural variants and absent or undetectable TERT expression were all independently associated with relative TL elongation (Fig. 3b,c) . Although DAXX has been linked to telomere length and ALT 19, 41 , DAXX mutations (n = 51/6,835) and deletions (n = 5/6,835) did not associate with TL.
Because of the strong correlation between ATRX and TL, we performed a thorough investigation of alterations affecting this gene. In addition to nonsynonymous mutations and deletions, we detected ATRX structural variants from WGS data in 5% of samples from the core set (n = 26/473). To detect ATRX structural variants across the extended set, we used DNA copy number calls to detect breakpoints in ATRX (Supplementary Fig. 8b ). Despite the high detection threshold of this method (34% sensitivity, 100% specificity), ATRX structural variants were predicted in 70 of 6,835 samples (1%). ATRX fusion transcripts were found in seven extended set samples ( Supplementary  Fig. 8c) . ATRX was the 5′ gene partner in five fusion genes, and the fusions were predicted to result in retention of <10% of the ATRX protein sequence. ATRX was the 3′ partner in two fusion transcripts, and functional protein domains were retained in both.
We observed a significant decrease in ATRX expression in samples showing ATRX mutations, deletions, fusions and structural variants compared to cases with wild-type ATRX (Fig. 4a) . We found that all of types of ATRX alteration associated with significantly longer TLs than wild-type ATRX, consistent with the previously established association between ATRX deactivation and ALT (Fig. 4b) .
Recent studies found that ATRX knockdown results in higher levels of TERRA 42 . We estimated TERRA levels using RNA sequencing in the extended set and in 566 non-neoplastic samples. Our results showed a significantly higher fraction of TERRA-expressing samples in all groups of ATRX-altered samples ( Fig. 4c; Fisher's exact test P < 0.05) than in ATRX wild-type samples. TERRA expression was associated with relative TL elongation (two-sided t-test TL ratio 1.13, 95% CI 1.07-1.017, P < 0.0001). Significantly more samples expressed TERRA in tumors lacking TERT expression than in tumors expressing TERT (Fisher's exact OR 0.73, 95% CI 0.65-0.82, P < 0.0001). In contrast, comparison of TERRA levels in tumor samples and their matched normal controls (n = 596, Fisher's exact test P > 0.05) showed no significant differences.
Absence of TERT expression and ATRX deactivation.
Owing to the association between somatic ATRX and TERT alterations with TL, we grouped tumors in the extended set as TERT-expressing (TERT expr , n = 5,001/6,835, 73%) and ATRX-or DAXX-altered (ATRX/DAXX alt , n = 309/6,835, 5%). ATRX or DAXX mutations were found in 210 TERT expr samples, representing 3% of the cohort. These events were mostly nontruncating, while ATRX and DAXX mutations in TERT-negative cases were mostly truncating (Supplementary Note and Supplementary Fig. 9a ). ATRX and DAXX mutants expressing TERT showed higher telomerase signature scores than did ATRX/ DAXX alt samples lacking TERT expression (Supplementary Fig. 9b ). On the basis of these observations, we included these samples in the TERT expr category. The remaining 22% of samples had neither detectable TERT expression nor somatic alterations in ATRX or DAXX (WT/WT, n = 1,525/6,835; Fig. 5a ). Both TERT expr and WT/WT groups showed significantly higher telomerase signature scores than the ATRX/DAXX alt group ( Fig. 5b; two-sided t-test P < 0.0001). The intermediate telomerase activity levels and variable TLs suggested that the WT/WT group comprises a heterogeneous set of tumors, some of which may have undergone ALT through mechanisms independent of ATRX and DAXX. The WT/WT samples were most frequent among pheochromocytoma (n = 141/160, 88%), kidney papillary (n = 113/161, 70%), kidney chromophobe (n = 52/65, 80%) and thyroid cancer (n = 343/449, 79%). Seven of the 101 WT/WT samples in the core set showed a somatic TERT alteration in absence of TERT expression, including TERTp mutation (n = 1), TERT amplification (n = 2) and TERTp or TERT structural variant (n = 4).
TERT expr samples showed relative TL attrition in most cancer types, ATRX-altered samples tended to show relative TL elongation, and WT/WT samples demonstrated cancer-type-dependent patterns (Fig. 5c) . For example, WT/WT sarcoma (TL ratio 1.27, 95% CI 1.1-1.47) and glioma (TL ratio 1.33, 95% CI 1.01-1.75) samples showed relative TL elongation, whereas WT/WT thyroid (TL ratio 0.69, 95% CI 0.62-0.77), kidney chromophobe (TL ratio 0.74, 95% CI 0.67-0.81) and kidney clear cell (TL ratio 0.57, 95% CI 0.48-0.67) cancer samples showed relative TL attrition. Patterns of relative TL change from the WT/WT group indicate that some tumors may be detected before having acquired immortalized cells 43 or that other mechanisms to develop ALT exist.
Because this analysis suggests that the prevalence of ALT may be underestimated by ATRX or DAXX inactivation alone, we sought to compare the prevalence of ATRX and DAXX alteration to published prevalence of ALT across 26 cancer types, including 40 histological subtypes 44 (Supplementary Table 6 ). The prevalence of ALT exceeded that of ATRX and DAXX alterations in seven histological subtypes and was reduced in two, reinforcing the notion of cancer-type-specific and ATRX-and DAXX-independent ALT mechanisms. Each group was compared to the ATRX WT group; ***P < 0.0001; **P < 0.001; *P < 0.05, two-sided t-test (a,b) or two-sided Fisher's exact test (c). Boxes, interquartile range (IQR); center lines, median; whiskers, maximum and minimum or 1.5× IQR. Mut, mutation; sv, structural variation; fus, fusion; del, deletion. a n a ly s i s
To better understand alternative mechanisms that may contribute to telomere maintenance, we conducted an unsupervised search for TL ratio-associated somatic alterations within the WT/WT group in the extended set. This analysis recovered strong associations between relatively long TL, IDH1 (TL ratio 1.8, 95% CI 1.39-2.33, FDR = 0.0001) and TP53 (TL ratio 1.39, 95% CI 1.23-1.57, FDR < 0.0001), both of which were also identified in the analysis of TL length in the entire data set. The finding of IDH1 may reflect a glioma-specific effect. In addition to IDH1 and TP53, RB1 (TL ratio 1.5, 95% CI 1.2-1.87, FDR = 0.001) and MDM2 (TL ratio 1.51, 95% CI 1.14-2, FDR = 0.01) were revealed to associate with relatively long TLs. The finding of RB1 is consistent with experimental data demonstrating marked elongation of telomeres in Rb1-deficient mice independent of telomerase 45, 46 . In the opposite direction, somatic alterations in PBRM1 (TL ratio 0.67, 95% CI 0.55-0.83, FDR = 0.001), NRAS (TL ratio 0.68, 95% CI 0.52-0.9, FDR = 0.02) and VHL (TL ratio 0.7, 95% CI 0.57-0.85, FDR = 0.002) were associated with relative TL shortening (Fig. 5d) .
We compared global genomic characteristics of the three groups and found that WT/WT samples contained fewer copy number segments (two-sided t-test P < 0.0001; Supplementary Fig. 9c ) and had a lower mutation rate (two-sided t-test P < 0.0001; Supplementary  Fig. 9d ) than TERT expr and ATRX/DAXX alt samples. Survival analyses within cancer types showed better survival in WT/WT than in TERT expr sarcoma and thyroid carcinoma (Supplementary Fig. 9e ). Telomerase activity scores in WT/WT samples in these two cancer types were significantly lower (two-sided t-test P = 7.0 × 10 −7 and P = 7.8 × 10 −3 , respectively), suggesting that telomerase activity might represent a relevant prognostic factor in these cancers.
Telomere position effect
After the quantification of TLs, we sought to relate TL to gene expression changes using the extended set and 566 adjacent tissue normal samples (Supplementary Table 7) . We first investigated the telomere position effect (TPE), a phenomenon that describes TL-mediated transcriptional regulation 47 . Expression of genes close to telomeres was negatively correlated with TL, and this effect was attenuated as distance to telomeres increased (Fig. 6a,b) . Because tumors had shorter telomeres on average than matched normal samples, genes ). ***P < 0.0001; **P < 0.001; *P < 0.01, two-sided t-test. FDR adjustment for multiple testing was used in d. Boxes, interquartile range (IQR); center lines, median; whiskers, maximum and minimum or 1.5× IQR. a n a ly s i s close to telomeres showed higher expression in tumor than normal tissue (Fig. 6c) . The TPE was not detectable beyond the distance of 10 million bp from telomeres (Fig. 6a,b) .
To identify gene sets associated with TL attrition and elongation in an unsupervised fashion, we associated gene expression to TL attrition and elongation. Pathway analysis of the top 500 correlated genes indicated that relative TL attrition and elongation were associated with immunoreactive and proliferative signatures, respectively (Fig. 6d) . These results may reflect differences in telomere maintenance rather than telomere attrition and elongation and describe frequently observed patterns of expression across cancers, potentially related to aggressiveness of tumors 48 .
DISCUSSION
This study represents, to our knowledge, the largest in-depth integrative analysis of TL and related somatic alterations performed to date. As expected, tumor TLs were shorter than normal tissue TLs, and TL was inversely correlated with age in both tumor and nonneoplastic tissues. Among TERT expr tumors, 32% carried at least one of three TERT abnormalities: promoter mutation, amplification or chromosomal rearrangement. Of TERT expr and wild-type tumors, 91% were TERTp methylated, compared to 40% of tumors lacking TERT transcription. This paradoxical association between TERTp methylation and increased TERT expression may result from loss of binding of CTCF, a transcriptional repressor reported to bind to the unmethylated TERTp 49 . Structural TERT variants have been documented 15, 50, 51 , and we detected these across several cancer types previously unknown to show such abnormalities, including sarcoma, prostate and liver carcinoma. Hepatitis B virus and adeno-associated virus type 2 integration in TERT were found in about 5% of hepatocellular carcinomas 52 . The absence of similar observations in other virus-related cancers (including head and neck, bladder and gastric cancers) suggests that this mechanism is specific to liver cancer; we thus did not consider it in this study.
Whether TERT expression translates directly to active telomerase activity is unclear. Only the full-length transcript (as opposed to known isoforms) has been found to activate telomerase 32, 39 . TERC expression is additionally needed for telomerase activity 53 . An estimated 5-10% of TERC and TERRA transcripts carry the poly(A) tails required for oligo(dT)-primer-based RNA sequencing quantification [54] [55] [56] . We detected TERC and TERRA expression across our cohort, suggesting that if expression is sufficiently high, transcripts can be detected using conventional RNA sequencing approaches. Lacking telomerase activity data, we sought to infer telomerase activity using a gene-signature-driven approach. Our results suggested a positive correlation between TERT expression and telomerase activity, corroborating recent findings in bladder cancer 35 . We also observed a positive correlation between TERC expression and telomerase activity, as well as increased telomerase activity in TERT-expressing tumors compared to tumors with ATRX or DAXX alterations and WT/WT tumors. This gene signature may serve as a useful proxy for estimating telomerase activity using transcriptional profiles.
Deactivation of ATRX and/or DAXX has been related to ALT 19, 20, 57 and was observed in 5% of cases in our core set. A detailed review of ATRX somatic changes showed a large spectrum of potentially protein truncating changes, including inactivating mutations, deletions and structural variants. DAXX alterations were much less frequent. Our analysis reinforced the association of inactivated ATRX or DAXX and ALT, demonstrating relative TL elongation in samples affected by somatic alterations in one of these two genes and a higher frequency of TERRA expression in tumors with these alterations.
The 22% of cases that lacked detectable TERT expression and known ALT-related abnormalities provide a notable result from our analysis. It is plausible that TERT transcription below the currently applied detection threshold may be sufficient for telomere maintenance, that not all tumors harbor immortalized cells with a telomere maintenance mechanism 43 or that additional telomere maintenance mechanisms exist. Such mechanisms may involve some RB1 and TP53 alterations, as somatic changes in these genes were associated with telomere elongation within this group. Notably, WT/WT tumors were mostly pheochromocytoma and paraganglioma, kidney chromophobe a n a ly s i s and papillary thyroid tumors. Pheochromocytoma is generally (>90%) labeled benign. Chromophobe renal cell carcinoma and papillary thyroid cancer are malignant tumors but are generally well differentiated, infrequently metastasize and demonstrate a more favorable outcome than other cancer types [58] [59] [60] [61] . Future studies are needed to elucidate the telomere maintenance mechanisms, or lack thereof, in these tumor types. In summary, our analysis has broadened the scope of potential TERT-activating changes, completed the spectrum of ATRX-truncating alterations and provided new insights into the telomere biology of tumors lacking these classic alterations. These findings extend current understanding of telomere biology and open avenues for functional studies of how to target this crucial pathway in oncogenesis.
URLs. PRADA fusion portal, http://www.tumorfusions.org.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
ONLINE METhODS
Sample selection. The 31 cancer types included in this study were: acute myeloid leukemia (LAML); adrenocortical carcinoma (ACC); bladder urothelial carcinoma (BLCA); brain lower-grade glioma (LGG); breast invasive carcinoma (BRCA); cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC); cholangiocarcinoma (CHOL); colon adenocarcinoma (COAD); esophageal carcinoma (ESCA); glioblastoma multiforme (GBM); head and neck squamous cell carcinoma (HNSC); kidney chromophobe (KICH); kidney renal clear cell carcinoma (KIRC); kidney renal papillary cell carcinoma (KIRP); liver hepatocellular carcinoma (LIHC); lung adenocarcinoma (LUAD); lung squamous cell carcinoma (LUSC); lymphoid neoplasm diffuse large B cell lymphoma (DLBC); ovarian serous cystadenocarcinoma (OV); pancreatic adenocarcinoma (PAAD); pheochromocytoma and paraganglioma (PCPG); prostate adenocarcinoma (PRAD); rectum adenocarcinoma (READ); sarcoma (SARC); skin cutaneous melanoma (SKCM); stomach adenocarcinoma (STAD); testicular germ cell tumors (TGCT); thymoma (THYM); thyroid carcinoma (THCA); uterine carcinosarcoma (UCS); uterine corpus endometrial carcinoma (UCEC); uveal melanoma (UVM).
We removed cases that were annotated as having bad DNA quality or failing a quality-control (QC) step. We also removed technical replicates and samples from patients who had prior systematic treatment or revised pathological diagnosis. Tumor and control samples from each patient were paired, selecting a blood-derived control if both blood and solid tissue control were available. A comprehensive sample selection procedure can be found in the Supplementary Note, and a schematic is shown in Supplementary Figure 1a. Data generation. Raw RNA and DNA sequencing data (n = 35,978 samples) were downloaded from CGHub 62 and processed through a flowr 63 pipeline consisting of various components depending on the data type. Processed clinical, gene expression, DNA methylation, copy number segmentation and mutation data were downloaded and compiled from previously published TCGA papers, the Firehose data portal (Broad Institute) and the TCGA data portal (NIH). GISTIC 64 was employed on the processed segmentation files to infer somatic copy number changes. A more detailed description of the data collection and generation process is described in the Supplementary Note.
Telomere length quantification. Quantification of telomere length (TL) was performed using TelSeq 21 . Briefly, this tool counts the number of reads containing any (range k to ) amount of telomeric repeats (n k ), or TTAGGG [k,] , and the GC-adjusted coverage s. The quotient of the number of telomeric repeats and the GC-adjusted coverage is then multiplied by the average chromosome length c (c = 332,720,800/46,000, in kb), resulting in the estimated telomere length (l) in kb.
We used a k of 7, as per the author's recommendations. Using the default settings from TelSeq, this calculation is done individually for each read group within a sample. In order to calculate the average TL for each sample, the weighted average length was used, supplying the total number of reads in each read group as weight. RNA-seq BAM files were also processed using TelSeq (k = 7) to obtain an estimate of TERRA expression. Because TERRA expression demonstrated a bimodal distribution, and over 40% of samples lacked any detectable TERRA expression, TERRA expression was dichotomized using a cutoff of 0.
TERTp mutation detection. We used GATK 65 pileup to determine bases mapping to each position 200 bp upstream of the TERT transcription start site (chr. 5:1295162-1295404, hg19) in 1,771 tumor samples and matched normal controls from 20 cancer types where whole-genome or low-pass whole-genome sequencing data were available.
We first performed an unsupervised screen, testing each of 200 sites in every tumor and matched normal. For each site, we required a minimum coverage of 10 reads, minimum variant allele fraction of 25% in tumor and maximum variant allele fraction of 2% in normal. Fisher's test was used to determine significance, and a threshold of 0.05 was used. Samples with TERT expression below a threshold of two reads were filtered from the analysis. Four sites demonstrated significance in at least one sample: C228, C250, C242/243 and C169. We then determined the nucleotides called in each of the affected sites, and found that all affected sites underwent a C>T transition.
Next, we performed a supervised analysis using the four sites above in all tumor samples to determine TERTp status. For each tumor sample, we required a minimum coverage of 6 bp across all aforementioned sites in order to call TERTp status. Because all GBM samples lacked any coverage at the C169 site, this site was excluded in this tumor type. In order to call the mutation, we required at least 15% variant reads.
There was sufficient coverage for TERTp mutation calling in 903 samples, and we detected TERTp mutations in n = 183, including chr. 5: 1,295,228 C>T (n = 128), 1,295,250 C>T (n = 49), 1,295,242/1,295,243 C>T (n = 5) and 1,295,169 C>T (n = 1). Next, we combined these calls with n = 1077 TERTp calls obtained by targeted sequencing from adrenocortical carcinoma (n = 91), lower-grade glioma (n = 287), hepatocellular carcinoma (n = 196), melanoma (n = 119) and papillary thyroid carcinoma (n = 384) for a grand total of n = 1,807 TERTp mutation calls. In cases where WGS and targeted sequencing based calls disagreed, we selected the mutated variant.
Structural variant detection.
We used SpeedSeq 66 to call structural variants in WGS-based BAM files. The SpeedSeq pipeline was built using our in-house pipeline building tool Flowr 63 , and ran on a high-performance computing cluster at the University of Texas MD Anderson Cancer Center. BAM files were realigned using BWA-MEM 67 . The resulting calls in VCF format were filtered against matching normal. Only somatic events with at least three supporting reads were retained.
Because we were interested only in variants involving TERT (chr. 5:1253287-1315162, including 20 kb upstream of the TSS) and ATRX (chr. X:76760356-77041719), variants not overlapping one of these regions were excluded. An overview of all included variants can be found in Supplementary Table 2.
Fusion transcript detection. All fusion transcripts were detected using the pipeline of RNA-seq Data Analysis (PRADA) as previously described 29, 30 . Briefly, chimeric fusion transcripts were detected from the realigned BAM files mapped to a combined genome and transcriptome reference on the basis of the evidence of both discordant read pairs and fusion-spanning reads, where discordant read pairs represent the paired read-ends that map uniquely to two protein coding genes, fusion-spanning reads mapped to the exon-exon junctions between two coding genes. Then the confidence of the detected fusion were evaluated on the basis of the number of junction-spanning reads and discordant read pairs, gene partner uniqueness, gene homology, open reading frame preservation, transcript allele fraction and presence of DNA breakpoints in adjacent distal regions. All fusions harboring TERT or ATRX transcripts were considered bona fide fusion calls on the basis of the criteria described previously and therefore included in this study. A summary of included fusions can be found in Supplementary Table 2. TERT isoform detection. PRADA-aligned RNA-seq BAM files were available for n = 6,625 (97% of the extended set) samples, missing data on ovarian carcinoma (OV, n = 27) and prostate cancer (PRAD, n = 175).
We applied the mixture of isoforms (MISO) model 40 to each BAM to infer the relative abundance of full-length and β − TERT transcripts in each sample. Because the detection of isoforms is limited by the high GC-content of TERT combined with a 3′ bias by regular poly(A) enrichment RNA-seq protocol and unevenly spread expression across exons, we limited the analysis to exons 6-9 only and applied a coverage threshold of at least 12 reads within this region. These filters reduced the sample cohort to 24% (n = 1,201) of 5,001 tumors classified as TERT-expressing in the extended set. The exon model used to infer isoform abundance has been included in Supplementary Table 4 . Briefly, the β − isoform skips exons 7 and 8, and samples demonstrating predominantly β − transcripts should therefore demonstrate low coverage in exons 7 and 8 relative to 6 and 9 and show junction-spanning reads between exons 6 and 9.
Structural variant breakpoint super-enhancer and ChIP-seq analysis. Super-enhancer coordinates were downloaded from dbSuper 26 , accessed 15 March 2016. At this time, the database consisted of 65,950 super-enhancers across 107 tissue and/or cell types. After excluding low-complexity regions and telomeres and centromeres, regions in this database spanned approximately 18% of the genome. We used the UCSC genome browser 68 to browse the database and inspected the position of each of the juxtaposed genomic coordinates. This analysis found overlapping super-enhancers in 11/17 TERTp structural variants, and this was significantly more than expected by chance (chi-square test P = 0.001).
Publicly available ChIP-seq data were downloaded from the NIH Roadmap Epigenomics Mapping Consortium 28 . This data set consists of 183 biological samples from multiple individuals, sequencing centers, tissue and/or cell types and was further consolidated into 111 unique epigenomes. We identified n = 44 tissue and/or cell types with H3K27ac (enhancer) sequencing, n = 53 tissue and/or cell types with H3K4me1 (enhancer) sequencing and n = 55 tissue and/or cell types with H3K27me3 sequencing (inactive promoter). Altogether, we collected data from 71 distinct tissue and/or cell types across these three marks. Collected BED files were converted to BAM format and a total number of reads was computed for each sample and mark.
ChIP-seq data were downloaded as previously described. For each structural variant proximal (adjacent to the TERTp) and distal breakpoint (juxtaposed to the TERTp), we calculated the number of reads mapping to each of three histone marks (H3K27ac, H3K27me3 and H3Kme1) individually within each tissue and cell/type. Breakpoint coordinates were flanked on either side to form a 2-kb bin. Read counts were normalized to RPKM on the basis of the total number of reads for each mark and sample. We then compared the RPKM between distal and proximal breakpoints for each histone mark for each set of breakpoint coordinates individually (Supplementary Fig. 4d ), and subsequently with all breakpoints pooled together (Fig. 2b) . P values were calculated using a two-sided t-test for each mark individually.
Telomerase activity signature inference. Microarray gene expression data from eight dedifferentiated liposarcoma samples were downloaded from the Gene Expression Omnibus (GEO GSE20559). We performed a differential expression analysis comparing four telomerase positive and four telomerase negative (ALT) samples and identified 1,302 genes associated with telomerase positive tumors (fold-change ≥ 1.5). Intersecting with 420 genes associated with embryonic stem cells 69 , which are known to be telomerase positive, further refined this gene set and resulted in a list of 43 genes (Supplementary Table 4 ). Validation of the resulting gene signature using matched telomerase activity and RNA sequencing data from eleven urothelial cell carcinoma cell lines provided some evidence that this gene signature may be able to predict telomerase activity (ρ = 0.58, P = 0.07; Supplementary Fig. 7a) . A detailed description of the strategy used to infer a telomerase activity signature may be found in the Supplementary Note.
Candidate gene selection and telomere length association. To narrow down the list of candidate genes and increase the FDR-adjusted significance threshold, we took the union of the MutSig2CV 70 gene list (FDR < 0.05, downloaded and compiled from publicly available Firehose analyses) from all cancer types, and combined this list with genes within significant GISTIC 2.0 peaks (FDR < 0.10) after filtering peaks larger than 1 Mb.
Each gene was annotated as putative tumor suppressor or putative oncogene depending on the mutational patterns (Supplementary Note) or whether it was found within an amplification or deletion peak. In those cases where the mutation-based classification did not agree with the copy number-based classification (e.g., a gene with highly frequent hotspot mutations was found in a deletion peak), we selected to prefer the mutation-based classification. Genes lacking classification and genes where the mutation-based classification demonstrated contradicting evidence (e.g., genes that could be classified as either tumor suppressors or oncogene) were dropped, unless the gene was present on a list of telomere-related genes, in which case it was annotated as a significantly mutated gene. The list of candidate genes was further reduced by removing multiple genes from the same peak, additionally leaving only those genes closely tied to telomere function when multiple genes present in the peak (e.g., shelterin complex genes) and genes that were also found in the MutSig2CV gene list. The final list of genes can be found in Supplementary Table 5 .
For each candidate gene and sample, we determined whether it was altered depending on the classification. For genes classified as tumor suppressors, we classified samples as altered when they showed a somatic mutation, a focal deletion or both. For genes classified as oncogenes, we classified the sample as altered when they showed a somatic mutation, focal amplification or both. For genes classified as significantly mutated gene only somatic mutations were counted. Each candidate gene was then correlated to the TL ratio in all samples and within diseases individually. This analysis was repeated specifically within samples classified as double wild type.
Statistical analysis. Summary statistics of telomere length are provided in mean, s.d. and range by tumor type and tissue type. Telomere length was transformed to the logarithmic scale owing to skewness. A linear mixed model was used to estimate mean telomere length of tumor and normal samples for each tumor type. Age, center and sex were included as covariates in all models. Interactions between disease type and center, gender and age were assessed and none were significant. The 'patient' variable was modeled as a random effect in the mixed model to account for correlation between samples from the same patient.
Linear regression was used to correlate TL ratio to various biomarkers. Backwards elimination was then used to select the best model with only significant factors. All tests were two-sided, and P values ≤ 0.05 were considered statistically significant.
Spearman correlation was used to associate TERT expression and methylation and to correlate gene expression and TL. A two-sided t-test was used to correlate somatic alterations and TL. P values were adjusted for multiple testing using the Benjamini-Hochberg FDR. An FDR of 0.25 or lower was considered statistically significant.
Survival curves were estimated and plotted using the Kaplan-Meier method. Log-rank tests were used to compare curves between groups. Univariate and multivariate Cox modeling were used to compute hazard ratios and confidence intervals.
All statistical analyses were carried out using SAS version 9 (SAS Institute) and R (R Foundation for Statistical Computing).
Data availability.
A complete overview of all gene fusions can be found on our fusion web portal (http://tumorfusions.org/). Raw RNA and DNA sequencing data (n = 35,978 samples) were downloaded from CGHub 62 . Processed clinical, gene expression, DNA methylation, copy number segmentation and mutation data were downloaded and compiled from previously published TCGA papers, the Firehose data portal (Broad Institute, http://gdac.broadinstitute.org/) and the TCGA data portal (NIH). All TCGA data are publicly available through NCI Genomic Data Commons (https://gdc.cancer.gov/). Cases used in this study and their telomere length estimates are listed in Supplementary Table 1. 
